File(s) under permanent embargo
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Version 2 2024-06-04, 08:28
Version 1 2021-06-17, 15:03
journal contribution
posted on 2024-06-04, 08:28 authored by G Morris, Ken WalderKen Walder, S Kloiber, P Amminger, Michael BerkMichael Berk, CC Bortolasci, M Maes, BK Puri, AF CarvalhoThe endocannabinoidome in neuropsychiatry: Opportunities and potential risks
History
Journal
Pharmacological ResearchVolume
170Article number
ARTN 105729Pagination
1 - 24Location
NetherlandsPublisher DOI
ISSN
1043-6618eISSN
1096-1186Language
EnglishPublication classification
C1 Refereed article in a scholarly journalPublisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicinePharmacology & PharmacyEndocannabinoid receptorsNeuro-immuneOxidative stressNeurotoxicityAffective disordersDepressionBipolar disorderPsychiatryNeuroscienceSchizophreniaNeurodegenerationCANNABINOID CB2 RECEPTORACID AMIDE HYDROLASELONG-TERM DEPRESSIONPROTEIN-COUPLED RECEPTORMESSENGER-RNA EXPRESSIONEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISDIACYLGLYCEROL-LIPASE-ALPHAINDUCED INSULIN-RESISTANCEHETEROTRIMERIC G-PROTEINSBLOOD-BRAIN-BARRIER110999 Neurosciences not elsewhere classified920410 Mental HealthInstitute for Innovation in Mental and Physical Health and Clinical TranslationSchool of MedicineFaculty of Health3209 Neurosciences3214 Pharmacology and pharmaceutical sciences420313 Mental health services200409 Mental health
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC